Healthy Volunteer
Conditions
Brief summary
This was a Phase 1a, single-center, double-blind, randomized, placebo-controlled study of the safety, tolerability, PK, and PD of single ascending doses of RB006 administered as an SC injection, with and without IV RB007 (an active control agent for RB006), in healthy young volunteers. The study originally planned to enroll 4 cohorts of 8 subjects each (N=32); however, upon review cohort (Cohort 1-A) was necessary in order to fully define the PK profile of SC RB006. Therefore, 36 subjects were enrolled in this study. Each cohort was balanced by sex with no more than 2/3 of one sex enrolled in any particular cohort (i.e., 5 of 8 subjects in each cohort). No subject participated in \>1 dose group, and progression to the next higher dose only occurred if the prior dose level was well tolerated, as assessed by a Safety Review Committee (SRC)
Interventions
DRUGSubcutaneous RB006 0.5 mg/kg
Subcutaneous RB006 0.5 mg/kg
DRUGSubcutaneous RB006 1.0 mg/kg
Subcutaneous RB006 1.0 mg/kg
DRUGSubcutaneous RB006 3.0 mg/kg
Subcutaneous RB006 3.0 mg/kg
DRUGSubcutaneous RB006 2.0 mg
* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration * Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration.
DRUGPlacebo
Placebo
Sponsors
Regado Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. An Institutional Review Board (IRB)-approved informed consent was signed and dated prior to any study-related activities. 2. Subject was between the ages of 18 and 45 years, inclusive. 3. Subject was a female with a negative urine or serum pregnancy test or postmenopausal for at least 1 year prior to randomization. 4. Subject had a body mass index (BMI) between 18 kg/m2 and 32 kg/m2 (weight/\[height\]2) and was ≥50 kg and ≤120 kg total body weight. 5. Subject had normal (or abnormal and clinically insignificant) laboratory values at Screening. 6. Subject was medically normal with no significant abnormal findings at the Screening physical examination. 7. Subject had the ability to understand the requirements of the study and a willingness to comply with all study procedures. 8. Subject had not consumed and agreed to abstain from taking any dietary supplements or nonprescription drugs 9. Subject had not consumed and agreed to abstain from taking any prescription drugs 10. Subject had not consumed alcohol-containing beverages for 3 days prior to CRU admission 11. Subject had not consumed grapefruit or grapefruit juice within the 14 days prior to CRU admission 12. Subject had not used tobacco or nicotine-containing products within 6 months prior to CRU admission
Exclusion criteria
1. Evidence or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal (GI), cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic, endocrine, or psychiatric disease. 2. Any evidence or history of intracranial bleeding, aneurysm, or thrombotic or hemorrhagic stroke. 3. Any known individual or family history of a bleeding diathesis or coagulopathy. 4. Active or expected menstruation during the Treatment Phase (females only). 5. History of thrombocytopenia associated with abnormal bleeding or risk of a bleeding event, or screening or baseline platelet count \<100,000/mm3. 6. History of thrombocytosis associated with a thrombotic event or risk for a thrombotic event, or screening or baseline platelet count \>600,000/mm3. 7. Endoscopically confirmed peptic ulcer disease within 3 years of CRU admission or GI bleeding within 3 months of CRU admission, including a positive stool for occult blood at Screening or Baseline. 8. Urinary tract bleeding within 3 months of CRU admission, including microscopic hematuria on screening or baseline urinalysis. 9. Unusual or prolonged bleeding (e.g., gum bleeding, nosebleeds, easy bruising), as documented on the Self-Reported Bleeding Questionnaire, at Screening. 10. Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within 3 months of CRU admission. 11. Severe persistent hypertension (systolic pressure \>180 mmHg or diastolic pressure \>110 mmHg). 12. Baseline hemoglobin \<12.0 g/dL for males or \<11.0 g/dL for females; prothrombin time (PT) greater than the ULN; or aPTT greater than the ULN. 13. Clinically significant liver dysfunction (e.g., as evidenced by elevated liver function tests). 14. Clinically significant renal dysfunction (e.g., estimated glomerular filtration rate \<60 mL/min or serum creatinine \>1.5 mg/dL). 15. History of illicit drug abuse in the past year or current evidence of such abuse in the opinion of the Investigator. 16. Positive findings on urine drug screen. 17. Positive findings for human immunodeficiency virus, hepatitis B, and/or hepatitis C at Screening. 18. Pregnant or lactating. 19. Acute illness within 1 week of CRU admission. 20. A history of alcohol abuse in the past year relative to CRU admission. 21. Donated plasma within 7 days of study drug administration. 22. Donated 1 or more pints of blood (or equivalent blood loss) within 6 weeks prior to study drug administration. 23. Use of an investigational drug within 30 days prior to CRU admission or prior REG1 Anticoagulation System exposure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome of this study using SC RB006 with and without RB007 in healthy volunteers was safety as determined by Treatment Emergent Adverse Events | 10 days |
Secondary
| Measure | Time frame |
|---|---|
| Outcome of this study using SC RB006 with and without RB007 in healthy volunteers was pharmacodynamics as determined by change from baseline in aPTT | Pre-dose, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216 (and if applicable, 264) hours post RB006 dose |
| Outcome of this study using SC RB006 with and without RB007 in healthy volunteers was pharmacokinetics as determined by Maximum Observed Plasma Concentration (Cmax) | Pre-dose, 1, 2, 3, 6, 9, 12, 15, 18, 24, 30, 36, 48, 60, 72, 84, 96, 120, 144, 168, and 216 (and if applicable, 264) hours post-RB006 dose |
| Outcome of this study using SC RB006 with and without RB007 in healthy volunteers was safety as determined by Serious Adverse Events | 10 days |
Countries
United States
Outcome results
None listed